Magnetar Financial LLC Takes $26.73 Million Position in Drugs Made In America Acquisition II Corp. $DMII

Magnetar Financial LLC purchased a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the fourth quarter, Holdings Channel.com reports. The firm purchased 2,700,000 shares of the company’s stock, valued at approximately $26,730,000.

A number of other large investors have also made changes to their positions in the company. OMERS ADMINISTRATION Corp acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $9,900,000. Sculptor Capital LP acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $4,950,000. Verition Fund Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $1,980,000. PEAK6 LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $990,000. Finally, Clear Street Group Inc. acquired a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter valued at approximately $1,797,000.

Analysts Set New Price Targets

DMII has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Trading Up 0.0%

Shares of DMII opened at $10.09 on Wednesday. The company’s 50 day moving average is $10.04. Drugs Made In America Acquisition II Corp. has a 52 week low of $9.86 and a 52 week high of $10.09.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.